Ofloxacin, like other systemic fluoroquinolones, exhibits broad-spectrum in vitro potency and good in vivo activity. Members of the family Enterobacteriaceae and staphylococci that are responsible for most nosocomial meningitis or ventriculitis (1) are highly susceptible to this compound. Previous studies have shown that members of this new class of drugs are widely distributed in the human body (3) . Some of them, such as pefloxacin, readily diffuse into cerebrospinal fluid (CSF) (7) . In a recent study, M. W. Sobieski and W. M. Scheld demonstrated that ofloxacin penetrates into CSF of rabbits with experimental Haemophilus influenzae meningitis, with a rapid bactericidal effect (Program Abstr. 25th Intersci. Conf. Antimicrob. Agents Chemother., abstr. no. 216, 1985) . Moreover, preliminary studies in humans performed after oral administration (5, 6) confirmed these experimental results. These in vitro and in vivo studies prompted us to evaluate the diffusion of intravenous ofloxacin into CSF of patients with meningitis or ventriculitis who were undergoing treatment with conventional antibiotherapy.
(A preliminary report of this work has been presented [J. C. Pioget, M. Wolff Drug assay. Concentrations of ofloxacin in plasma and CSF were determined by a specific high-performance liquid chromatography assay with spectrofluorometric detection. The chromatographic system consisted of a pump (Shimadzu LC 6A), an automatic sample injector (WISP 710 B; Waters Associates, Inc., Milford, Mass.), a Lichrospher RP 18 column (5 ,m, 250 mm; Merck & Co., Inc., Rahway, N.J.), and a spectrofluorometric detector (Shimadzu RF 530) coupled to a Shimadzu CR 3A integrator; excitation and emission wavelengths were set to 290 and 500 nm, respectively. The degassed mobile phase was a mixture of acetonitrile, PIC A reagent (Waters), and monopotassic phosphate buffer (10 mM) adjusted to pH 2.5 with formic acid (80:20:900, vol/vollvol) with a flow rate of 1 ml/min. A 200-,lI sample of plasma or CSF to which was added 5 or 2.5 jig, respectively, of norfloxacin (used as the internal standard) and 1 ml of 0.067 M phosphate buffer (pH 7.4) was extracted with 7 ml of methylene chloride. After centrifugation, the organic layer was evaporated under a stream of nitrogen to dryness; the dry residue was dissolved in 200 ,ul of the mobile phase, and 20 ,ul was injected. Plasma and saline (for CSF determinations) standard curves were linear up to 8 and 4 ,ug/ml, respectively. Within-day and day-to-day variations in assay were 3 and 6% for plasma samples spiked with 1 and 0.5 Rg of ofloxacin per ml and 1.5 and 4.5% for saline samples spiked with 1.0 and 0.2 ,ug of ofloxacin per ml. The detection limit was 0.01 ,ug/ml. No analytical interference occurred with the following drugs added to plasma samples at a concentration of 10 ,ug/ml: amoxicillin, cefsulodin, cefotaxime, piperacillin, vancomycin, gentamicin, amikacin, chloramphenicol, and metronidazole.
Pharmacokinetic analysis. In the five patients with ventriculitis, data were analyzed according to the following equations. Half-life (t1/2) was calculated from the equation t1/2 = 0.693/Az, where Az is the terminal-phase rate constant, determined by the least-square method as the slope of the terminal monoexponential decline in drug concentration in plasma or CSF versus time. The area under the plasma or CSF concentration-time curve (AUC) was calculated by the trapezoidal rule from the end of the infusion to time t of the last sample and extrapolated to infinity according to the formula: AUC,_. = C,/Xz, where C, is the concentration of the drug in plasma or CSF in the last sample taken at time t. Since ofloxacin was administered every 12 h, AUC was also calculated from the first measured concentration to the 12-h value (AUCO_.12), and the diffusion of ofloxacin into CSF was estimated by the ratio of the CSF AUCO, 12 to the plasma AUC-12.
RESULTS
Mean peak levels in plasma were 5.9 + 0.6 ,ug/ml during the acute stage of the disease and 4.3 + 0.5 ,ug/ml during the late stage. Mean trough levels were 1.2 ± 0.2 and 0.7 ± 0.2 ,ug/ml, respectively. Concentrations in plasma and CSF for each patient are shown in Tables 1 and 2 . Mean plasma levels at the time CSF was drawn decreased from 3.7 ± 0.4 to 0.8 ± 0.2 ,ug/ml and from 4.2 ± 0.6 to 0.57 ,ug/ml between 0.5 and 12 h after the third infusion during the two stages. The highest levels of CSF were observed in the second group of patients when specimens were taken 3 h after the end of the infusion: 1.8 ± 0.3 pg/ml when the meninges were most inflamed and 1.1 ± 0.3 pg/ml during the late stage. Percentages of penetration, expressed as the ratios of concentrations in CSF to simultaneous levels in plasma, are shown in Tables 1 and 2 . These values were 22 + 3, 33 ± 4, 26 ± 3, and 18 + 4% during the acute stage and 20% (n = 2), 30 + 11%, 25% (n = 2), and 21% (n = 2) during the late stage of the disease.
The main pharmacokinetic parameters for ofloxacin in plasma and CSF in the five patients with ventriculitis are shown in Table 3 . Plasma and CSF terminal t112 values were 7.1 ± 0.8 and 10.2 ± 1.7 h, respectively. Diffusion into the CSF was relatively slow, since the highest levels were observeq between 3 and 6 h after the third infusion. These levels rangid from 1 to 2.1 ,ug/ml. At 12 h after the end of the infusion, concentrations in CSF were 0.9 ± 0.08 ,ug/ml (range, 0.7 to 1.2 ,ug/ml). The ratio of the CSF AUCO12 to the plasma AUCO12 was 73 ± 6. Ofloxacin levels in ventricular fluid and plasma for these five patients are shown in Fig.  1 . One patient had a slight transient increase of hepatic enzymes. No other adverse effect was observed. DISCUSSION In this study, ofloxacin appeared to diffuse into CSF of patients with bacterial meningitis or ventriculitis. As with other antibiotics, diffusion was higher when the meninges were most inflamed. Among the 10 patients who received the drug during both periods of the disease, levels in CSF were approximately 1.5 higher in the earlier stage of meningitis. Diffusion appeared to be slow and variable, since the mean peak level was attained 3.6 ± 1.0 h after the end of the infusion. The ratios of concentrations in CSF to simultaneous levels in plasma increased from 30 ± 2 to 134 ± 17% between 0.5 and 12 h after the infusion. This result is explained by the slow diffusion of ofloxacin in CSF and by a -mg/l- (6) . In a study involving nine patients, concentrations in CSF ranged from 50 to 60% of those found in plasma between 2 and 12 h after a 200-mg dose given orally every 12 h over 2 to 8 days (5). Three hours after a single 300-mg dose, the mean levels in plasma and CSF in six patients with purulent meningitis were 4.36 and 1.65 pLg/ml (2) . Therefore, in these studies the concentrations of ofloxacin in CSF were slightly lower when the drug was administercd orally rather than by infusion despite the high bioavailability of this quinolone (3). This finding could be the consequence of a higher concentration gradient when the drug is administered as a slow infusion. The plasma protein binding of ofloxacin is only 10%, a factor that may increase the ability of the drug to penetrate the blood-brain barrier (7) . On the basis of these data, we suggest that (i) ofloxacin readily diffuses into CSF of patients with bacterial meningitis or ventriculitis, (ii) the diffusion appears to be slightly lower when the meninges are less inflamed, and (iii) concentrations in CSF exceed the MICs for most pathogens responsible for purulent meningitis. However, there is a wide range of concentrations among patients, and levels in CSF should be monitored if the drug is to be used as the main treatment. In addition, further studies are needed to evaluate the clinical usefulness of ofloxacin in the treatment of bacterial meningitis caused by susceptible pathogens.
